Ambry Genetics Creates New Business Division to Support Biopharmaceutical Research

FOR IMMEDIATE RELEASE

Ambry Genetics
15 Argonaut
Aliso Viejo, CA 92656

Aliso Viejo, CA, January 28, 2008 - Ambry Genetics, a recognized leader in comprehensive clinical genetic testing, has created a new division to support Pharmaceutical Research, Clinical Research Organizations (CROs) and Clinical Trials.

The role that genetics is taking in drug development and Clinical Trials is expanding as new technologies enable rapid analysis of genetic causes of drug response and toxicity. An individual’s genetic make-up can have a significant impact on how they respond to certain drugs. Ambry Genetics has created a separate division focused on providing genetic testing and bio-informatics to researchers.

Ambry Genetics has the capabilities to perform SNP analysis, custom mutation panels, drug metabolism panels, full gene sequencing, genome sequencing and gene expression analysis. Testing can be performed at all levels of regulatory compliance from basic research, GLP compliant to clinical testing in our CLIA Licensed and CAP Accredited laboratory.

Ambry’s President & CEO, Charles L.M. Dunlop, explains: "Ambry has supported Pharmaceutical Research and Clinical Trials with genetic testing for many years. The creation of this division will allow us to have a focused team approach to helping solve the complex genetic questions in drug development and Clinical Trials management. We have made significant investment in state of art technology and bio-informatics to ensure our Pharmaceutical Services clients enjoy the same world class service as our diagnostic clients."


About Ambry Genetics ®

Ambry Genetics is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry leads in clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information about Ambry Genetics, visit ambrygen.com.

Press Contact:
Aaron Schmidt
Sr Manager, Communications
aschmidt@ambrygen.com
949 457 4679

Search Results

Start your search...